{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T21:38:33Z","timestamp":1783201113949,"version":"3.54.6"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives:<\/jats:title>\n                  <jats:p>To examine whether the lipid parameters are predicting factors for human immunodeficiency virus (HIV)\u2013associated lipodystrophy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Whole-body fat compositions of HIV-positive patients receiving stavudine-containing antiretroviral regimens (n = 79) were determined. Lipodystrophy was defined as a ratio of trunk fat mass\/lower limb fat mass greater than 2.28. Blood samples were analyzed for total cholesterol (TC), triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), small-dense LDL-C (sdLDL-C), apoAI, apoB, lipoprotein(a), and CD4 cell counts. Large-buoyant LDL-C (lbLDL-C) was calculated (LDL-C minus sdLDL-C).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Twenty-six patients were classified as having lipodystrophy. The mean values of triglycerides, HDL-C, sdLDL-C, apoB, TC\/HDL-C, apolipoprotein (apo) B\/apoAI, and sdLDL-C\/lbLDL-C showed significant differences between patients with and without lipodystrophy (P &amp;lt; .02). Using logistic regression analysis, sdLDL-C\/lbLDL-C was identified as a significant predictor of lipodystrophy (P &amp;lt; .001). At a ratio of 0.554, the odds ratio was 17.8 with a likelihood ratio of 5.5.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>The sdLDL-C\/lbLDL-C ratio is an excellent marker for indicating lipodystrophy in HIV-infected patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1309\/ajcpe5i3keltbxej","type":"journal-article","created":{"date-parts":[[2013,9,17]],"date-time":"2013-09-17T19:23:52Z","timestamp":1379445832000},"page":"506-515","source":"Crossref","is-referenced-by-count":10,"title":["Small-Dense LDL Cholesterol\/Large-Buoyant LDL Cholesterol Ratio as an Excellent Marker for Indicating Lipodystrophy in HIV-Infected Patients"],"prefix":"10.1093","volume":"140","author":[{"given":"Pornpen","family":"Srisawasdi","sequence":"first","affiliation":[{"name":"1Division of Clinical Chemistry, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanida","family":"Suwalak","sequence":"additional","affiliation":[{"name":"1Division of Clinical Chemistry, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chonlaphat","family":"Sukasem","sequence":"additional","affiliation":[{"name":"2Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anchalee","family":"Chittamma","sequence":"additional","affiliation":[{"name":"1Division of Clinical Chemistry, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anothai","family":"Pocathikorn","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somlak","family":"Vanavanan","sequence":"additional","affiliation":[{"name":"1Division of Clinical Chemistry, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apichaya","family":"Puangpetch","sequence":"additional","affiliation":[{"name":"2Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siwalee","family":"Santon","sequence":"additional","affiliation":[{"name":"2Division of Pharmacogenomics and Personalized Medicine, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasun","family":"Chantratita","sequence":"additional","affiliation":[{"name":"4Divison of Virology, Department of Pathology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasisopin","family":"Kiertiburanakul","sequence":"additional","affiliation":[{"name":"5Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Kroll","sequence":"additional","affiliation":[{"name":"6Quest Diagnostics, Madison, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,10,1]]},"reference":[{"key":"2023012006111484000_b1-1400506","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/S0140-6736(05)62505-6","article-title":"Decline in deaths from AIDS due to new antiretrovirals","volume":"349","author":"Hogg","year":"1997","journal-title":"Lancet"},{"key":"2023012006111484000_b2-1400506","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society\u2013USA panel","volume":"308","author":"Thompson","year":"2012","journal-title":"JAMA"},{"key":"2023012006111484000_b3-1400506","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(06)68337-2","article-title":"Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries","volume":"367","author":"Braitstein","year":"2006","journal-title":"Lancet"},{"key":"2023012006111484000_b4-1400506","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"2023012006111484000_b5-1400506","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMra041811","article-title":"Cardiovascular risk and body-fat abnormalities in HIV-infected adults","volume":"352","author":"Grinspoon","year":"2005","journal-title":"N Engl J Med"},{"key":"2023012006111484000_b6-1400506","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1086\/649897","article-title":"Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study","volume":"201","author":"Worm","year":"2010","journal-title":"J Infect Dis"},{"key":"2023012006111484000_b7-1400506","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/00002030-199912240-00002","article-title":"Fat distribution and metabolic changes in patients with HIV infection","volume":"13","author":"Safrin","year":"1999","journal-title":"AIDS"},{"key":"2023012006111484000_b8-1400506","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1046\/j.1468-1293.2003.00159.x","article-title":"HIV lipodystrophy: prevalence, severity and correlates of risk in Australia","volume":"4","author":"Miller","year":"2003","journal-title":"HIV Med"},{"key":"2023012006111484000_b9-1400506","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/QAI.0b013e31824330cb","article-title":"Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors","volume":"59","author":"Alam","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023012006111484000_b10-1400506","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","article-title":"Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1\u2013infected patients","volume":"32","author":"Lichtenstein","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023012006111484000_b11-1400506","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"2023012006111484000_b12-1400506","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00002030-200001070-00005","article-title":"Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study","volume":"14","author":"Saint-Marc","year":"2000","journal-title":"AIDS"},{"key":"2023012006111484000_b13-1400506","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMra025261","article-title":"Acquired and inherited lipodystrophies","volume":"350","author":"Garg","year":"2004","journal-title":"N Engl J Med"},{"key":"2023012006111484000_b14-1400506","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1086\/381783","article-title":"Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?","volume":"189","author":"Fontas","year":"2004","journal-title":"J Infect Dis"},{"key":"2023012006111484000_b15-1400506","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.beem.2011.04.004","article-title":"Lipid metabolism in treated HIV infection","volume":"25","author":"Dub\u00e9","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2023012006111484000_b16-1400506","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/01.qai.0000143599.64234.15","article-title":"Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine","volume":"38","author":"Shlay","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023012006111484000_b17-1400506","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1097\/01.aids.0000183629.20041.bb","article-title":"Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides","volume":"19","author":"Dub\u00e9","year":"2005","journal-title":"AIDS"},{"key":"2023012006111484000_b18-1400506","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jacl.2008.08.442","article-title":"Lipoprotein changes in HIV-infected antiretroviral-na\u00efve individuals after starting antiretroviral therapy: ACTG Study A5152s Stein: lipoprotein changes on antiretroviral therapy","volume":"2","author":"Stein","year":"2008","journal-title":"J Clin Lipidol"},{"key":"2023012006111484000_b19-1400506","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/01.CIR.0000131511.50734.44","article-title":"Atherogenic lipoprotein particles in atherosclerosis","volume":"109","author":"Carmena","year":"2004","journal-title":"Circulation"},{"key":"2023012006111484000_b20-1400506","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1067\/mhj.2002.126119","article-title":"Significance of small dense low-density lipoproteins and other risk factors in patients with various types of coronary heart diseases","volume":"144","author":"Koba","year":"2002","journal-title":"Am Heart J"},{"key":"2023012006111484000_b21-1400506","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2265.2008.03407.x","article-title":"Small, dense low-density lipoproteins are predictors of cardio- and cerebrovascular events in subjects with the metabolic syndrome","volume":"70","author":"Rizzo","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023012006111484000_b22-1400506","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2005.12.002","article-title":"Significance of small dense low-density lipoprotein-cholesterol concentrations in relation to the severity of coronary heart diseases","volume":"189","author":"Koba","year":"2006","journal-title":"Atherosclerosis"},{"key":"2023012006111484000_b23-1400506","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cca.2012.09.010","article-title":"Small dense LDL: an emerging risk factor for cardiovascular disease","volume":"414","author":"Hirayama","year":"2012","journal-title":"Clin Chim Acta"},{"key":"2023012006111484000_b24-1400506","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.clinbiochem.2009.05.018","article-title":"Hepatic insulin resistance, metabolic syndrome and cardiovascular disease","volume":"42","author":"Meshkani","year":"2009","journal-title":"Clin Biochem"},{"key":"2023012006111484000_b25-1400506","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cca.2005.12.026","article-title":"Lipid and lipoprotein dysregulation in insulin resistant states","volume":"1\u20132","author":"Avramoglu","year":"2006","journal-title":"Clin Chim Acta"},{"key":"2023012006111484000_b26-1400506","first-page":"929","article-title":"Use and interpretation of anthropometric indicators of nutritional status","volume":"64","author":"WHO Working Group","year":"1986","journal-title":"Bull World Health Organ"},{"key":"2023012006111484000_b27-1400506","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0140-6736(03)12656-6","article-title":"An objective case definition of lipodystrophy in HIV-infected adults: a case-control study","volume":"361","author":"Carr","year":"2003","journal-title":"Lancet"},{"key":"2023012006111484000_b28-1400506","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4158\/EP11139.OR","article-title":"Human immunodeficiency virus\u2013associated lipodystrophy: an objective definition based on dual-energy x-ray absorptiometry-derived regional fat ratios in a South Asian population","volume":"18","author":"Asha","year":"2012","journal-title":"Endocr Pract"},{"key":"2023012006111484000_b29-1400506","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jocd.2009.12.004","article-title":"Longitudinal study of body composition of 101 HIV men with lipodystrophy: dual-energy X-ray criteria for lipodystrophy evolution","volume":"13","author":"Degris","year":"2010","journal-title":"J Clin Densitom"},{"key":"2023012006111484000_b30-1400506","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jocd.2010.01.005","article-title":"Fat mass ratio: an objective tool to define lipodystrophy in HIV-infected patients under antiretroviral therapy","volume":"13","author":"Freitas","year":"2010","journal-title":"J Clin Densitom"},{"key":"2023012006111484000_b31-1400506","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: risks and impact on clinical decision making","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023012006111484000_b32-1400506","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/QAI.0b013e31816d9ba1","article-title":"The associations of regional adipose tissue with lipid and lipoprotein levels in HIV-infected men","volume":"48","author":"Wohl","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023012006111484000_b33-1400506","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/QAI.0b013e318164227f","article-title":"Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women","volume":"48","author":"Currier","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023012006111484000_b34-1400506","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/QAI.0b013e31824476e1","article-title":"Small dense lipoproteins, apolipoprotein B, and risk of coronary events in HIV-infected patients on antiretroviral therapy: the Swiss HIV Cohort Study","volume":"60","author":"Bucher","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023012006111484000_b35-1400506","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/0140-6736(93)92464-5","article-title":"High plasma lipoprotein (a) in HIV-positive patients","volume":"341","author":"Constans","year":"1993","journal-title":"Lancet"},{"key":"2023012006111484000_b36-1400506","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/01.qai.0000220164.72113.12","article-title":"Antiretroviral therapy in HIV-positive women is associated with increased apolipoproteins and total cholesterol","volume":"42","author":"Rimland","year":"2006","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2023012006111484000_b37-1400506","doi-asserted-by":"crossref","first-page":"E490","DOI":"10.1152\/ajpendo.00118.2003","article-title":"Alterations in lipid kinetics in men with HIV-dyslipidemia","volume":"285","author":"Reeds","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2023012006111484000_b38-1400506","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1056\/NEJMcp070061","article-title":"Clinical practice: hypertriglyceridemia","volume":"357","author":"Brunzell","year":"2007","journal-title":"N Engl J Med"},{"key":"2023012006111484000_b39-1400506","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jac\/dkn251","article-title":"HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options","volume":"62","author":"Mallewa","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"2023012006111484000_b40-1400506","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00075197-200209000-00005","article-title":"Measuring body fat distribution and content in humans","volume":"5","author":"Goodpaster","year":"2002","journal-title":"Curr Opin Clin Nutr Metab Care"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/140\/4\/506\/48794760\/ajcp_140_4_506.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/140\/4\/506\/48794760\/ajcp_140_4_506.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T06:15:32Z","timestamp":1674195332000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/140\/4\/506\/1760793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,10,1]]},"published-print":{"date-parts":[[2013,10,1]]}},"URL":"https:\/\/doi.org\/10.1309\/ajcpe5i3keltbxej","relation":{},"ISSN":["1943-7722","0002-9173"],"issn-type":[{"value":"1943-7722","type":"electronic"},{"value":"0002-9173","type":"print"}],"subject":[],"published-other":{"date-parts":[[2013,10,1]]},"published":{"date-parts":[[2013,10,1]]}}}